Real-World data shows ravulizumab keeps PNH in check after switch
NCT ID NCT05274633
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study looked at 120 Italian patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched from the older drug eculizumab to the newer ravulizumab. Researchers tracked changes in a blood marker called LDH to see how well the new treatment controlled the disease in everyday medical practice. The goal was to confirm that ravulizumab works as well in real life as it does in controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Brescia, Italy
-
Clinical Trial Site
Catania, Italy
-
Clinical Trial Site
Lecce, Italy
-
Clinical Trial Site
Ragusa, Italy
-
Clinical Trial Site
Roma, Italy
-
Clinical Trial Site
Salerno, Italy
Conditions
Explore the condition pages connected to this study.